Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
O Abani, A Abbas, F Abbas, M Abbas, S Abbasi… - The Lancet, 2021 - thelancet.com
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
J Chalmers, H Abo-Leyah, H Loftus, M Spears… - …, 2021 - discovery.dundee.ac.uk
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
DJ Dhasmana… - …, 2021 - research-repository.st-andrews.ac …
Background: In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
[HTML][HTML] Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial
RECOVERY Collaborative Group - Lancet (London, England), 2021 - ncbi.nlm.nih.gov
Background In this study, we aimed to evaluate the effects of tocilizumab in adult patients
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
admitted to hospital with COVID-19 with both hypoxia and systemic inflammation. Methods …
Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): preliminary results of a randomised, controlled, open-label, platform trial
Background Tocilizumab is a monoclonal antibody that binds to the receptor for interleukin
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
(IL)-6, reducing inflammation, and is commonly used to treat rheumatoid arthritis. We …
Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial
VC Veiga, JAGG Prats, DLC Farias, RG Rosa… - bmj, 2021 - bmj.com
Objective To determine whether tocilizumab improves clinical outcomes for patients with
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
severe or critical coronavirus disease 2019 (covid-19). Design Randomised, open label trial …
Tocilizumab administration for the treatment of hospitalized patients with COVID‐19: a systematic review and meta‐analysis
C Kyriakopoulos, G Ntritsos, A Gogali, H Milionis… - …, 2021 - Wiley Online Library
Tocilizumab has been repurposed against the 'cytokine storm'in the setting of coronavirus
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
disease 2019 (COVID‐19). Our aim was to evaluate the efficacy of tocilizumab in the …
Tocilizumab in hospitalized patients with severe Covid-19 pneumonia
IO Rosas, N Bräu, M Waters, RC Go… - … England Journal of …, 2021 - Mass Medical Soc
Abstract Background Coronavirus disease 2019 (Covid-19) is associated with immune
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
dysregulation and hyperinflammation, including elevated interleukin-6 levels. The use of …
Tocilizumab in hospitalized patients with COVID-19: a meta analysis of randomized controlled trials
Background To date, only dexamethasone has been shown to reduce mortality in
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …
coronavirus disease-19 (COVID-19) patients. Tocilizumab has been recently added to the …
Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study
Background Tocilizumab (TCZ), a humanized monoclonal antibody targeting the interleukin-
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …
6 (IL-6) receptor, has been proposed for the treatment of COVID-19 patients; however …